Evaluation of the effectiveness of PHR-160 spray in hospitalized patients with Covid-19
IRCT; 2021-01-11; TrialID: IRCT20201223049816N1
Clinical Trial Register
| ICTRP | ID: ictrp-IRCT20201223049816N1
ABSTRACT
Condition
covid-19.COVID-19;U07.1
Intervention
Intervention 1 Intervention group 1. Phr-160 spray group PHR spray160 micrograms per puff, 1 puff every 1 hour up to ten times a day, on days 1 to 10 (use of Damir is required) in addition to the latest covid-19 treatment in the country protocol. Due to the clinical symptoms, this treatment protocol can be continued for 10 days if needed. Intervention 2 Control group Standard emergency treatment based on protocol, Naproxen 250 mg , Famotidine 40 mg , Vitamin C 500 mg.Primary outcome:
Percentage of oxygen saturation in two intervention groups after randomization. Timepoint 1. After randomization at the beginning of the patient's arrival, and every day. Method of measurement Using Pulse Oximeter.Criteria
Inclusion criteria Both sexesAges 15-75
Oxygen saturation percentage between 88 and 93%.
Confirmation of 19 patients using RTPCR.
Confirmation of Covid-19 using CT scan
Signing a informed consent form
Exclusion criteria Attending another trial in the last three months
pregnancy/lactation
drug sensitivity to the ingredients in the intervention
very high severity of the disease in the emergency room (consciousness less than 15 / oxygen concentration less than 88%, etc)
history of chronic respiratory disease
Previous pulmonary embolism (last three months)
Collection:
Clinical trial registers
Database:
ICTRP
Year:
2021
Document Type:
Clinical Trial Register
Similar
MEDLINE
...
LILACS
LIS